Xilio Therapeutics reported strong Q1 2026 progress, advancing its cancer drug pipeline with key programs like XTX501 and XTX601 moving toward clinical trials. The company plans to submit an IND for XTX501 mid-2026 and start Phase 1 trials in late 2026, targeting solid tumors. XTX601 showed promising preclinical data for gastrointestinal cancers, and a multi-specific masked T cell engager targeting prostate cancer is also in development. Financially, Xilio raised cash via a follow-on offering, ending Q1 with $150.3 million and expects funding through early 2028, supported by milestones under collaborations with AbbVie and Gilead.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
